New Racing Bulls F1 team boss ‘shocked' after ‘amazing' promotion
The domino effect of Horner being relieved of his duties saw Laurent Mekies – formerly RB team principal – promoted to Red Bull F1 CEO. Permane, who was previously racing director at RB, is now the team boss.
The 58-year-old was previously with Alpine, in all its previous guises including championship-winning seasons with Benetton and Renault, for 34 years before being let go in July 2023. The engineer joined Racing Bulls at the start of last season.
'I had many reactions to the news, some shock, some pride,' Permane told Motorsport.com.
'It's amazing that they feel I'm capable and have the potential to lead this team.
'I deeply thank the Red Bull Austria senior management, Oliver Mintzlaff and Helmut Marko, and of course Laurent for recommending me, pushing me forward, his belief in me as well. It's been a great week.'
Racing Bulls are currently seventh in the constructors' championship and have two young talents in Liam Lawson and Isack Hadjar in the cockpit.
Alan Permane is Racing Bulls's new team principal (Getty Images)
Yuki Tsunoda was previously with the team for four years before being promoted in March to replace Lawson, dropped by Red Bull after just two races.
'It's a great team and I know that the senior Red Bull guys are extremely happy with the way the team is being run,' Permane added. 'They're very happy with our competitiveness.
'The target is to be top of the midfield, and we are certainly in a battle for that and we'll continue that fight throughout this year.'
The next race of the 2025 season is the Belgian Grand Prix at Spa-Francorchamps this weekend (25-27 July).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
%3Amax_bytes(150000)%3Astrip_icc()%2FTAL-lead-formula-one-budapest-ALISTKRISTINPOST0725-18276e45f37241cabb9e0a7a13cb0f0c.jpg&w=3840&q=100)
Travel + Leisure
4 hours ago
- Travel + Leisure
How to Plan Your First Trip to a Formula One Race, According to a Travel Advisor
Formula 1 has rapidly grown in popularity in the U.S. in recent years, but attending one of these high-profile races is still a relatively new consideration for most Americans. And as each race takes over its host city for multiple days, planning your trip can quickly turn into an overwhelming experience. As a travel advisor with experience curating Grand Prix weekends for clients, I've developed a few strategies to make sure your F1 weekend is all green lights. The Grand Prix track and harbor in Monte Carlo, Monaco. A Formula 1 race isn't just about the race on Sunday—it's a multi-day event that includes practice on Friday and qualifying races on Saturday, as well as tangential events. There are several phases that add context to the big race, and can make the whole experience even more thrilling. For example, certain tracks, like those in Monaco and Singapore, are filled with narrow streets on which overtaking (when a driver passes another driver) is difficult, so a driver's qualifying performance—which establishes their starting position—is extremely important. But if your interest is more casual or you're folding the race into a larger itinerary, you may opt for race day only. Each city that hosts a Formula One race brings its own personality to the event. Monaco, for example, is pure spectacle: mega yachts, private terraces, and top-tier people-watching. It's about the scene as much as the sport. Belgium's Circuit de Spa-Francorchamps, on the other hand, winds through farmlands and forest. It's a historic track that is best experienced with a guide by your side. One great hotel in the area to stay at is the Van der Valk Hotel Verviers. An alternative option for attendees is camping for the weekend. The Dutch Grand Prix is located in Zandvoort, Netherlands, a beachside location with plenty to do in the surrounding area. No matter which F1 race you are interested in, it's easy to find one that is personally interesting, whether it's for the social scene, track history, or unique traditions. Street market in Italy filled with racing souvenirs. Many F1 teams offer hospitality packages with pit-lane walks, team meet-and-greets, and insider access. The first time my family attended Zandvoort, our chosen experience included visiting the garages, meeting some of the drivers, and a personal ride to the track. Another option is the Paddock Club, a VIP program offered by F1 that typically includes private track access, fast-track entry, and dedicated hospitality lanes. Having attended logistically challenging races like Circuit of Spa-Francorchamps in Beligum, I can tell you that personalized services like this make a big difference. Singapore during F1 outside of major cities, like Monza in Italy or Suzuka in Japan, may require private drivers or heli-charters to avoid race-day headaches. At races where the track is close to an urban center—like Montreal, Singapore, or Zandvoort—you could feasibly hire a local driver or take public transportation to the gates. A travel advisor will take care of these logistics for you, but if you're mapping out your own trip, make sure your transportation is planned beforehand. Then you'll be free to tune into the spectacle around you, the strategy of each pit stop, and the sounds of engines that define one of the world's most thrilling traveling circuses. Kristin Chambers is a member of Travel + Leisure's A-List and specializes in destination celebrations, event travel, and family trips. You can create a tailor-made itinerary with Chambers at [email protected] .
Indianapolis Star
5 hours ago
- Indianapolis Star
National Chicken Wing Day deals. Where to get freebies and discounts in Indiana
National Chicken Wing Day is July 29. That means restaurant deals on one of America's favorite finger foods. Whether you like your wings party, whole, boneless or even veggie, there's an offer nearby to celebrate. According to the folks at National Calendar Day, the city of Buffalo, New York, in 1977 proclaimed July 29 to be National Chicken Wing Day. On July 29, members of the 7Rewards and Speedy Rewards loyalty programs can buy an eight-piece order of Boneless Wings and get eight wings free, or buy five Bone-in Wings and get five wings free. Also, when you buy two Red Bull drinks, you get five bone-in wings for free. Buy an order of Boneless Wings or Classic Bone-In Wings and get a second order for free with to-go or delivery through or the Applebee's app, Use promo code WINGDAY25 at checkout.. Buffalo Wild Wings customers can get six free traditional or boneless or wings with an order of $10 or more. The order applies to dine-in, online and in-app orders promo code FREEWINGS. Dine-in customers who buy 10 wings on July 29 can get an additional 10 for free. Through Aug. 3, Popeyes is offering a free six-piece Bone-In Wings order with the purchase of a six-piece order in-store. Customers buying a six-piece bone-in or boneless wings from delivery services such as DoorDash or Uber Eats until 2:59 a.m. Aug. 4 can get a six-piece order for free. Twin Peaks customers who buy six wings can get six wings free. The offer is available for dine-in guests all day on any style of wings — bone-in, boneless, breaded or naked — excluding Smoked & Grilled. Wings and Rings is offering 40% off all wings, including traditional, boneless and cauliflower wings. Wings Rewards members at Wings Etc. Grill & Pub can get double points on every order of jumbo or boneless wings on July 29. Scan your receipt to collect points in store. While ordering in-store. Double points are automatically added when ordering carryout or delivery through the app.
Yahoo
5 hours ago
- Yahoo
Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
Study utilizes Signatera to identify HR+, HER2-negative breast cancer patients for de-escalation of neoadjuvant chemotherapy AUSTIN, Texas, July 29, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive (HR+), HER2-negative breast cancer, who are endocrine responsive and test negative with Signatera. Sponsored by the Austrian Breast & Colorectal Cancer Study Group (ABCSG), TEODOR expects to enroll approximately 250 patients across 15 sites in Austria. Previous studies have demonstrated that patients who test Signatera-negative at diagnosis and then receive chemotherapy have excellent outcomes, with risk of recurrence at less than 5%. In an effort to reduce pre-operative chemotherapy, which can carry significant side effects, this study is designed to evaluate the efficacy of endocrine therapy compared to chemotherapy in patients who are Signatera-negative. After a four-week course of endocrine therapy, patients who are Signatera-negative and show a favorable endocrine sensitivity as measured by the Ki-67 proliferation index will be randomized to receive either additional endocrine therapy or chemotherapy. The primary endpoint of the study is the rate of neoadjuvant therapy response, assessed via pathological complete response (pCR) and modified Preoperative Endocrine Prognostic Index (PEPI) score across the endocrine therapy and chemotherapy arms of the trial. Secondary endpoints include long-term outcomes such as breast cancer recurrence and overall survival. "TEODOR is designed to examine whether we can use endocrine responsiveness and ctDNA status to optimize systemic therapy in the neoadjuvant setting," said ABCSG President, Michael Gnant, M.D., FACS, FEBS, who serves as professor of surgery, Comprehensive Cancer Center, Medical University of Vienna, and principal investigator of the TEODOR trial. "This study marks a critical step toward more personalized medicine, leveraging the latest technologies to improve patient care." "With the TEODOR trial, our goal is to identify patients who may be able to safely forgo chemotherapy," said Angel Rodriguez, M.D., medical director of oncology at Natera. "We are proud to collaborate with ABCSG on this important trial, and we hope this study will support the role of Signatera in guiding neoadjuvant therapy in breast cancer." About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit About ABCSG The ABCSG (Austrian Breast & Colorectal Cancer Study Group) is Austria's largest and best-known academic research organization, successfully conducting international clinical trials on breast and colorectal cancer — and, since 2013, also on pancreatic cancer. In addition, ABCSG is increasingly active in translational research. Our goal is to standardize diagnostics, treatment, and follow-up care throughout Austria and to offer patients the best and most up-to-date therapies. Since 1984, approximately 29,000 patients have participated in ABCSG studies worldwide. Multidisciplinarity is key to our global success and has helped improve cure rates and survival. Our clinical trials and translational research projects are conducted transparently and are monitored at every stage by ethics committees, regulatory authorities, and our highly professional and dedicated ABCSG team. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
